Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?

Affiliations

• ¹ Clinical Pharmacology, Genentech, South San Francisco, California (J.A.W.); University of Western Ontario, London, Ontario, Canada (B.L.U.); RIKEN Innovation Center, Yokohama, Kanagawa, Japan (Y.S.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, North Carolina (M.J.Z.-G.) ware.joseph@gene.com.
• ² Clinical Pharmacology, Genentech, South San Francisco, California (J.A.W.); University of Western Ontario, London, Ontario, Canada (B.L.U.); RIKEN Innovation Center, Yokohama, Kanagawa, Japan (Y.S.); and Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, North Carolina (M.J.Z.-G.).